相关实验视频

Updated: Jul 14, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

针对PD-L1阴性转移性非小细胞肺癌的最佳治疗策略:基于临床病理学和分子特征的决策指南

Mariana Malvicini¹, Maysa Silveira Vilbert², José N Minatta³

¹Cancer Immunobiology Laboratory, Instituto de Investigaciones en Medicina Traslacional, Universidad Austral-Consejo Nacional de Investigaciones Cientificas y Tecnologicas (CONICET), Buenos Aires, Argentina.

Current treatment options in oncology

|October 6, 2023

概括

免疫检查点抑制剂 (ICI) 提供了新的肺癌治疗方法. 这份指南有助于临床医生为PD-L1-阴性瘤非小细胞肺癌 (NSCLC) 患者选择最佳疗法.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症研究癌症研究

背景情况:

免疫检查点抑制剂 (ICI) 通过增强抗瘤免疫反应,改变了肺癌治疗.
ICI的功能是通过使用特定抗体阻止调节性细胞表面分子,如CTLA-4,PD-1和PD-L1.
抗PD-1疗法在非小细胞肺癌 (NSCLC) 患者中显示出显著的长期生存益处和持久反应.

研究的目的:

针对PD-L1-阴性NSCLC患者未定义的最佳治疗方法.
为管理PD-L1-阴性NSCLC提供临床决策指南.
综合最新的治疗数据,预后因素,预测生物标志物和这个患者群体的现实世界证据.

主要方法:

审查最近的临床试验数据关于ICI在NSCLC中的疗效.
对PD-L1-阴性NSCLC相关的预后因素和预测生物标志物的分析.
将现实世界的证据纳入治疗策略.

主要成果:

与抗PD1/PD-L1和化疗的联合治疗改善了与单独化疗相比的生存结果,无论PD-L1表达如何.
虽然高PD-L1表达在ICI中显示出有希望的结果,但PD-L1阴性NSCLC的最佳策略需要进一步定义.
有证据表明,需要基于个体患者数据的量身定制治疗方法.

结论:

针对PD-L1-阴性NSCLC的最佳治疗策略仍在不断发展.
建议综合现有数据的综合指南,以帮助临床医生在治疗决策中.
进一步的研究和现实世界的数据对于完善PD-L1-阴性NSCLC的治疗方案至关重要.

关键词:

晚期非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.抗瘤免疫疗法免疫疗法免疫检查点抑制剂免疫检查点抑制剂在PD-L1-阴性NSCLC患者中.编程死亡受体-1连接体 (PD-1L)编程死亡受体-1 (PD-1)

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...